Weill Cornell Medicine has received a three-year, $2.5 million grant from the Department of Defense to develop therapies with fewer side effects for triple-negative breast cancer, one of the most aggressive and difficult-to-treat breast cancers.
An NSAID-related compound called ampyrone appears to safely boost production of the pigment melanin in human skin, according to a preclinical study led by Weill Cornell Medicine and National Eye Institute investigators.
Glioma, a type of brain cancer, tends to progress toward greater malignancy due to an increasing tendency of the glioma cells to transform into immature, stem-cell-like states.
Researchers have identified a site where a commonly used anesthetic binds to sodium ion channels, revealing a molecular mechanism that may explain how these drugs dampen communication between neurons.
An artificial intelligence system that operates like a collaborative team of medical experts could accelerate clinical trial design, one of the most difficult steps in drug development.
Patients with advanced prostate cancer may need periodic imaging scans to catch tumor growth even with stable levels of prostate-specific antigen, a protein in the blood that doctors routinely monitor for cancer progression.
Chronic psychological stress can help tumors evade immune attack through a chain of molecular events involving gut bacteria and viruses within those bacteria.
Loss of GATA6 – a transcription factor that controls which genes are turned on or off – can reprogram colorectal cancer cells into more primitive, adaptable states that can then spread to the liver and establish new tumors.
